|
gptkbp:instanceOf
|
gptkb:protein
cytokine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L03AB
|
|
gptkbp:CASNumber
|
9008-11-1
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
severe psychiatric disorders
|
|
gptkbp:discoveredBy
|
gptkb:Jean_Lindenmann
gptkb:Alick_Isaacs
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:encodedBy
|
IFNA genes
|
|
gptkbp:foundIn
|
blood plasma
|
|
gptkbp:halfLife
|
2-3 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon-alpha
|
|
gptkbp:inducedBy
|
apoptosis in infected cells
immune cell activation
expression of antiviral proteins
|
|
gptkbp:marketedAs
|
gptkb:Infergen
gptkb:Roferon-A
Intron A
|
|
gptkbp:mechanismOfAction
|
inhibits viral replication
modulates immune response
increases expression of MHC class I molecules
induces antiviral state in cells
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:producedBy
|
gptkb:leukocytes
|
|
gptkbp:promotion
|
gptkb:virus
double-stranded RNA
bacterial products
|
|
gptkbp:proteinFamily
|
gptkb:type_I_interferons
|
|
gptkbp:recipient
|
gptkb:interferon_alpha/beta_receptor
|
|
gptkbp:sideEffect
|
gptkb:depression
autoimmune disorders
fatigue
myelosuppression
flu-like symptoms
|
|
gptkbp:species
|
gptkb:human
gptkb:mouse
other mammals
|
|
gptkbp:structure
|
single-chain polypeptide
|
|
gptkbp:UNII
|
6G8XRS6194
|
|
gptkbp:usedFor
|
treatment of certain cancers
treatment of hepatitis C
treatment of chronic myelogenous leukemia
treatment of hepatitis B
treatment of Kaposi's sarcoma
treatment of hairy cell leukemia
treatment of malignant melanoma
|
|
gptkbp:bfsParent
|
gptkb:natural_killer_cells
gptkb:NK_cells
gptkb:hypereosinophilic_syndrome
gptkb:idiopathic_hypereosinophilic_syndrome
gptkb:Erdheim-Chester_disease
|
|
gptkbp:bfsLayer
|
7
|